Welcome to Insider Trades Daily, glad you're here! Every day, more than 500,000 investors use this newsletter to track insider buying and selling across major public companies. It’s a simple way to see what the people closest to the business are doing with their own money. Before we start sending your daily updates, there’s just one quick thing left to do. Please confirm your subscription using the link below. Click Here to Confirm Your Subscription to Insider Trades Daily It takes a few seconds and helps make sure your newsletter shows up where it belongs, your inbox, not a spam folder. Once you’re confirmed, we’ll take it from there and deliver clear, no-nonsense insider trading insights straight to you. Start Receiving Insider Information The InsiderTrades.com Team P.S. If there's anything we can do to improve your experience, please let us know by replying to this email.
Exclusive Story from MarketBeat
2 Ways to Play the Big Pharma Patent CliffWritten by Nathan Reiff. Date Posted: 5/15/2026. 
Key Points
- Big pharma faces uncertainty for nearly $200 billion in drug sales that will lose their exclusivity in the coming years.
- The ensuing M&A flurry as firms try to shore up their drug portfolios may present opportunities for investors.
- Two broad industry-focused ETFs, XBI and IBB, can be a place to start.
- Special Report: Elon Musk’s $1 Quadrillion AI IPO
Major pharmaceutical firms like Pfizer Inc. (NYSE: PFE) and Novo Nordisk A/S (NYSE: NVO) have been spending heavily on smaller companies in the space in recent months (the former completed an acquisition of weight loss drug maker Metsera in November 2025). While M&A activity is sometimes a sign of aggressive expansion, in this case it may also reflect a response to a threat: a patent cliff that could lead to the loss of exclusivity for many of the world’s top-selling drugs in the years ahead. Drugs with collective annual sales of nearly $175 billion are expected to face this challenge over the next six years, and the figure rises much higher when smaller names are included. Though this is a serious obstacle for many of the largest pharma companies, it is also an opportunity for investors. The coming years are likely to bring an increasingly urgent wave of M&A activity, which could create new winners in the space. While it may be difficult for investors to predict which companies will come out on top, a pair of exchange-traded funds (ETFs) can help position investors to benefit from volatility in the industry. Broad Access to the U.S. Biotech Space, With a Focus on Smaller Firms
The SPDR S&P Biotech ETF (NYSEARCA: XBI) tracks the S&P Biotechnology Select Industry Index, a collection of biotech names from the S&P Total Market Index. The index uses a modified equal-weighted approach and provides exposure to biotech stocks across the market-capitalization spectrum. This matters for investors in the space, as smaller companies can sometimes deliver major breakthroughs and strong performance if a drug candidate is approved or a blockbuster new medicine emerges. Investors may want to note that mid-cap names make up about half of the portfolio, while small-caps account for nearly another 30%. XBI is more focused than a broader sector fund and is unique in that it is one of only a small number of ETFs specifically targeting the biotech industry. Its nearly 150 positions represent a wide cross-section of the U.S. biotechnology space and, as a result, can capture many domestic drugmaker gains. The largest holding in the fund remains under 2% of total invested assets, so diversification helps minimize the negative impact of underperformance by individual companies. On the other hand, a single company’s big gains may also be diluted in XBI’s overall performance. Still, XBI has done well in 2026, outperforming the broader market year-to-date (YTD) with returns of about 11% compared to about 9% for the S&P 500. The fund also provides a modest dividend. Given that this niche industry fund is relatively unique, investors may also find its 0.35% expense ratio reasonable. A Somewhat Different Approach for Broader Exposure, but Higher ConcentrationThe iShares Biotechnology ETF (NASDAQ: IBB), a direct rival to XBI, takes a somewhat different approach. While it is also generally focused on U.S. biotech names, it includes some international stocks such as Dutch biopharma firm argenx (NASDAQ: ARGX). It also holds a broader basket than XBI, with close to 250 positions overall. On the other hand, IBB is more heavily concentrated in a small number of names than its SPDR peer. The four largest holdings in its portfolio represent about 28% of invested assets. It also places more emphasis on large-cap names, with 61% of the portfolio allocated to larger firms. Like XBI, IBB pays out a modest dividend, which investors may view as an attractive buffer against some of the potential volatility in the biotech industry. In terms of performance, IBB has lagged behind XBI so far this year, returning only about 2% YTD. Over the past 12 months, though, its return of more than 40% is quite compelling and noticeably outpaces the S&P 500. One other consideration for IBB is that its expense ratio is higher than XBI's, at 0.44%. Investors looking for the broadest possible access to the biotech space may be willing to accept that trade-off and pay a bit more for this fund. However, its recent performance record is not as compelling as that of some other funds in the sector. Still, while IBB is more expensive than XBI, it remains cheaper than several other funds in the relatively narrow biotech category. |
0 Response to "Ready when you are"
Post a Comment